Skip to main content

Table 4 Bone marrow plasma cell percentage before and after VDC-1101 in 3 dogs experiencing stringent complete response

From: GS-9219/VDC-1101 - a prodrug of the acyclic nucleotide PMEG has antitumor activity inspontaneous canine multiple myeloma

  Pre-treatment Following final treatment
Patient AM No marrow elements present 2% well-differentiated plasma cells
Patient KW 40-50% atypical plasma cells <1% morphologically normal plasma cells
Patient SR 30% atypical plasma cells 2-5% well-differentiated plasma cells
  1. NB: patient AM’s myeloma diagnosis was made based on hypercalcemia, monoclonal gammopathy and the presence of multiple bony lytic lesions on radiographs.